US eye care company ISTA Pharmaceuticals announced plans to file an investigational new drug (IND) application with the FDA for its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis by the end of 2010. The company also released results from a Phase I/II study of the nasal spray showing that the drug was well tolerated and said that it plans to begin a new Phase II study this year. ISTA licensed North American rights to both opthalmic and nasal formulations of bepotastine besilate from Tanabe Seiyaku in 2006-2007. Read the company’s press release.
ISTA plans to file IND for nasal spray by end of year
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
